Madrigal Pharmaceuticals, Inc. (MDGL)
471.75
-5.16
(-1.08%)
USD |
NASDAQ |
Oct 09, 16:00
471.86
+0.11
(+0.02%)
Pre-Market: 20:00
Madrigal Pharmaceuticals Free Cash Flow : -209.28M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -209.28M |
| March 31, 2026 | -275.41M |
| December 31, 2025 | -193.02M |
| September 30, 2025 | -164.63M |
| June 30, 2025 | -308.39M |
| March 31, 2025 | -401.41M |
| December 31, 2024 | -462.03M |
| September 30, 2024 | -438.32M |
| June 30, 2024 | -455.82M |
| March 31, 2024 | -391.12M |
| December 31, 2023 | -325.71M |
| September 30, 2023 | -303.28M |
| June 30, 2023 | -277.13M |
| March 31, 2023 | -259.21M |
| December 31, 2022 | -225.07M |
| September 30, 2022 | -214.69M |
| June 30, 2022 | -201.20M |
| March 31, 2022 | -190.62M |
| December 31, 2021 | -184.13M |
| September 30, 2021 | -190.92M |
| June 30, 2021 | -193.17M |
| March 31, 2021 | -170.55M |
| December 31, 2020 | -157.90M |
| September 30, 2020 | -115.35M |
| June 30, 2020 | -78.82M |
| Date | Value |
|---|---|
| March 31, 2020 | -66.10M |
| December 31, 2019 | -41.80M |
| September 30, 2019 | -35.65M |
| June 30, 2019 | -29.58M |
| March 31, 2019 | -23.40M |
| December 31, 2018 | -25.53M |
| September 30, 2018 | -25.20M |
| June 30, 2018 | -24.90M |
| March 31, 2018 | -27.31M |
| December 31, 2017 | -22.44M |
| September 30, 2017 | -21.78M |
| June 30, 2017 | -26.07M |
| March 31, 2017 | -20.95M |
| December 31, 2016 | -17.61M |
| September 30, 2016 | -13.43M |
| June 30, 2016 | 30.31M |
| March 31, 2016 | 15.20M |
| December 31, 2015 | -3.142M |
| September 30, 2015 | -21.32M |
| June 30, 2015 | -74.41M |
| March 31, 2015 | -77.55M |
| December 31, 2014 | -79.07M |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Insmed, Inc. | -837.67M |
| United Therapeutics Corp. | 1.084B |
| Karyopharm Therapeutics, Inc. | -65.35M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 23.33M |
| Cash from Investing (Quarterly) | 34.20M |
| Cash from Financing (Quarterly) | 3.112M |
| Free Cash Flow Per Share (Quarterly) | 0.6545 |
| Free Cash Flow to Equity (Quarterly) | 18.64M |
| Free Cash Flow to Firm (Quarterly) | 27.02M |
| Free Cash Flow Yield | -1.71% |